KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced the presentation of full results from the Phase 3 adult efficacy and…Read More
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety
